<DOC>
	<DOC>NCT00694304</DOC>
	<brief_summary>The purpose of the study is to evaluate long-term safety and tolerability of Vortioxetine over a period of 52 weeks in patients with Major Depressive Disorder (MDD) having completed 8-week acute treatment.</brief_summary>
	<brief_title>Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder, Major</mesh_term>
	<mesh_term>Vortioxetine</mesh_term>
	<criteria>Patients who completed 8week shortterm treatment study for Major Depressive Episode, NCT00635219 / 11984A Any current psychiatric disorder other than MDD as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Ed., Text revision (DSMIV TR) Female patients of childbearing potential who are not using effective contraception Use of any psychoactive medication Other protocoldefined inclusion and exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Long-term</keyword>
	<keyword>Safety</keyword>
	<keyword>Open-label</keyword>
</DOC>